Post-GSK Deal, Novartis is Shopping for Bolt-on Acquisitions
Source: Washington Post
Apr 23, 2015
After concluding its $20 billion-plus three-part asset swap with GlaxoSmithKline, Novartis is reporting first quarter profits and back on the hunt for small acquisitions.
According to CEO Joe Jimenez, rather than looking for large transations, Novartis is looking for bolt-on acquisitions of $2 billion to $5 billion each.
According to the company, Novartis continues to stress a consistent focus on three core priorities – innovation, growth and productivity – when it comes to long-term strategy.
Read the Washington Post story
Join the discussion
We welcome your thoughtful comments.
All comments will display your user name.
Comments
No one has commented on this page yet.
RSS feed for comments on this page | RSS feed for all comments